Literature DB >> 15895784

Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis.

Reza Rahbar1, Sara O Vargas, Judah Folkman, Trevor J McGill, Gerald B Healy, Xiaolian Tan, Lawrence F Brown.   

Abstract

Vascular endothelial growth factor-A (VEGF-A) is known to play an important role in the angiogenic response essential for tumor growth in a variety of human and experimental tumors. This study was designed to investigate whether VEGF-A may play a role in the pathogenesis of recurrent respiratory papillomatosis (RRP). A retrospective study with institutional review board approval was performed at a tertiary care medical center on 12 patients with a history of laryngeal RRP. Their ages at the time of initial diagnosis ranged from 19 to 96 months (mean, 56 months). All patients had involvement of right and left true vocal cords. All patients required multiple endoscopic procedures (range, 4 to 66; mean, 12). Normal pediatric larynx samples from 5 autopsy patients were used as controls. Formalin-fixed, paraffin-embedded sections of laryngeal squamous papillomas from the 12 patients with a diagnosis of RRP and the 5 control patients were examined by in situ hybridization for the presence of messenger RNA (mRNA) for VEGF-A and vascular endothelial growth factor receptor 1 (VEGFR-1) and vascular endothelial growth factor receptor 2 (VEGFR-2). The biopsy specimens were from the true vocal cord (N = 10) or subglottis (N = 2) in the patients with RRP and consisted of large sections of larynx including the true vocal cord in the control patients (N = 5). Strong expression of VEGF-A mRNA was noted in the squamous epithelium of papillomas of all 12 patients. Strong expression of VEGFR-1 and VEGFR-2 was noted in the endothelial cells of the underlying vessels in all 12 patients. Neither strong labeling of VEGF-A mRNA nor labeling of its receptors wasnoted in the control patients. We conclude that the angiogenic growth factor VEGF-A is strongly expressed in the epithelium of squamous papillomas in RRP. Also, VEGFR-1 and VEGFR-2 mRNAs are strongly expressed by underlying vascular endothelial cells, suggesting an important role in the pathogenesis of RRP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15895784     DOI: 10.1177/000348940511400407

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  12 in total

1.  Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis.

Authors:  Magdalena Chirilă; Sorana D Bolboacă
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05       Impact factor: 2.503

2.  Office-based Management of Recurrent Respiratory Papilloma.

Authors:  Kevin M Motz; Alexander T Hillel
Journal:  Curr Otorhinolaryngol Rep       Date:  2016-03-31

Review 3.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

4.  Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis.

Authors:  James A DeVoti; David W Rosenthal; Rong Wu; Allan L Abramson; Bettie M Steinberg; Vincent R Bonagura
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

5.  Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.

Authors:  Armando Bedoya; Kristen Glisinski; Jeffrey Clarke; Richard N Lind; Charles Edward Buckley; Scott Shofer
Journal:  Am J Case Rep       Date:  2017-07-31

Review 6.  Current and future management of recurrent respiratory papillomatosis.

Authors:  Ryan Ivancic; Hassan Iqbal; Brad deSilva; Quintin Pan; Laura Matrka
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-01-14

Review 7.  Recurrent respiratory papillomatosis: A 2020 perspective.

Authors:  Jacob J Benedict; Craig S Derkay
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-03-13

8.  Opportunities and challenges for successful use of bevacizumab in pediatrics.

Authors:  Amy Barone; Joshua B Rubin
Journal:  Front Oncol       Date:  2013-04-29       Impact factor: 6.244

9.  Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis.

Authors:  Michael Mohr; Christoph Schliemann; Christoph Biermann; Lars-Henning Schmidt; Torsten Kessler; Joachim Schmidt; Karsten Wiebe; Klaus-Michael Müller; Thomas K Hoffmann; Andreas H Groll; Claudius Werner; Christina Kessler; Rainer Wiewrodt; Claudia Rudack; Wolfgang E Berdel
Journal:  Oncol Lett       Date:  2014-08-28       Impact factor: 2.967

Review 10.  Airway Papillomatosis: New Treatments for an Old Challenge.

Authors:  Nankee Kumar; Diego Preciado
Journal:  Front Pediatr       Date:  2019-09-18       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.